Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma

Allen, Julie; Stolle, Lars Bjørn

doi:10.1016/j.ejso.2014.10.055

Cited by 56 publications

(29 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, studies indicate that the sensitivity of SLNB for metastasis in high‐risk cutaneous SCC is inferior to that of melanoma. A 2014 systematic review of the literature examined 173 patients with high‐risk cutaneous SCC and found the specificity, sensitivity, and negative predictive value of SLNB in this cohort were 100%, 79%, and 96.1%, respectively . These results built on a previous systematic review of patients with similar findings .…”

Section: Managementmentioning

confidence: 58%

Review of high‐risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology

et al. 2016

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (SCC) is a malignancy that arises from epidermal keratinocytes. Although the majority of cutaneous SCC cases are easily treated without further complication, some behave more aggressively and carry a poor prognosis. These "high-risk" cutaneous SCCs commonly originate in the head and neck and have an increased tendency toward recurrence, local invasion, and distant metastasis. Factors for high-risk cutaneous SCC include large size (>2 cm), a deeply invasive lesion (>2 mm), incomplete excision, high-grade/desmoplastic lesions, perineural invasion (PNI), lymphovascular invasion, immunosuppression, and high-risk anatomic locations. Both the National Comprehensive Cancer Network (NCCN ) and the American Joint Committee on Cancer (AJCC) identify several of these high-risk features of cutaneous SCC. The purpose of this article was to review the high-risk features included in these guidelines, as well as their notable discrepancies and omissions. We also provide a brief overview of current prophylactic measures, surgical options, and adjuvant therapies for high-risk cutaneous SCC. © 2016 Wiley Periodicals, Inc. Head Neck 39: 578-594, 2017.

show abstract

Section: Managementmentioning

confidence: 58%

Review of high‐risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The false‐negative rate of SLNB in cSCC has been reported as 1.9–5.9% . For head and neck SCC alone, a false‐negative rate of 4.0–9.8% has been suggested .…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, unnecessary lymph node dissection would have been avoided in 12 patients if SLNB was conducted. Patients with positive SLN could benefit from early selected lymph node dissection and irradiation using the SLNB technique . Compared with lymph node dissection, the complications for selected lymph node dissection are reduced.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma

Maruyama

Tanaka

Fujisawa

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma is the second common cutaneous cancer, especially in the elderly. Sentinel lymph node biopsy is generally performed in breast cancers and cutaneous melanomas to detect occult nodal metastases. The benefit of sentinel lymph node biopsy in improving cutaneous squamous cell carcinoma prognosis is doubtful. One hundred and sixty-nine patients who underwent treatment for cutaneous squamous cell carcinoma between 2004 and 2015, and who were followed up for at least 6 months or developed metastases within the follow-up period were included. Forty-nine patients underwent sentinel lymph node biopsy, whereas 120 patients did not, including 13 who exhibited clinical lymph node metastases before treatment. Of these 49 patients, nine (18.4%) presented with sentinel lymph node metastasis, which occurred after treatment in three (6.1%) of them (false-negative). Among the 107 patients who did not undergo lymph node biopsy, 12 (11.2%) developed post-treatment metastases. The metastasis-free and disease-specific survival rates were not significantly different in those who did or did not undergo sentinel lymph node biopsy. Patients with clinical lymph node metastases had a higher risk compared with those without. Patients with T2-T4 tumors had a higher risk compared with those with T1 tumors. When selecting for those with T2 tumors or greater, the same lack of relationship was observed. In conclusion, in this small retrospective cohort, in patients with cutaneous squamous cell carcinoma, there were no significant differences in metastasis-free and disease-specific survival rates between those who did or did not undergo sentinel lymph node biopsy, regardless of T staging.

show abstract

“…One review of 173 patients with high-risk cSCC undergoing SLNB highlighted 79% sensitivity and 100% specificity, with negative predictive value of 96%. 61 Further systematic reviews have suggested the putative role for SLNB in cSCC may be limited to T2 lesions >2 cm diameter lesion only. 62 Traditionally, the complex drainage pattern of the neck and relatively small nodal size in the neck has led authors to suggest that the procedure is impractical in cSCC.…”

Section: Sentinel Lymph Node Biopsymentioning

confidence: 99%

High-risk Cutaneous Squamous Cell Carcinoma

Fitzgerald¹,

O’Neill²

2017

International Journal of Head and Neck Surgery

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma skin cancer worldwide. Cutaneous squamous cell carcinoma can potentially be treated fully with minimal morbidity when detected early; however, certain subtypes of cSCC have been shown to confer a poorer prognosis for patients. In these high-risk tumors, increased incidence of recurrence, as well as metastasis to local lymph nodes and distant sites, is seen as a result of certain patient characteristics and pathological features. While guidelines regarding the management of high-risk cSCC have been produced, no clear consensus management or prognostic algorithms exist. In this review, we discuss current definitions of high-risk cSCC, recommendations regarding the management of cSCC, and current guidelines.

show abstract

Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma

Cited by 56 publications

References 24 publications

Review of high‐risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology

Review of high‐risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology

Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma

High-risk Cutaneous Squamous Cell Carcinoma

Contact Info

Product

Resources

About